Oral dapoxetine demonstrates benefits in both men with premature ejaculation and their partners, report the authors of a multinational phase III clinical trial.
Oral dapoxetine demonstrates benefits in both men with premature ejaculation and their partners, report the authors of a multinational phase III clinical trial.
The data, presented during the European Association of Urology annual meeting in Milan, Italy, showed significant improvement in all four pre-defined endpoints for partners of 1,000 men treated with dapoxetine, 30 mg or 60 mg, versus placebo over a 25-week period.
At baseline, less than 5% of women reported that their perception of their partner’s control was “good” or “very good.” This percentage increased to 24.7% and 32.4% with dapoxetine, 30 mg and 60 mg, respectively (vs. 14.5% with placebo; p<.001), reported lead author Jacques Buvat, MD, of the Centre d’Etude et de Traitement de la Pathologie de l’Appareil Reproducteur et de la Psychosomatique (CETPARP) in Lille, France.
More than 42% of women reported that they were “quite a bit” or “extremely” distressed by the timing of their partner’s ejaculation at baseline. This decreased to 22.3% and 18.3% with dapoxetine, 30 mg and 60 mg, respectively (vs. 29.5% with placebo; p<.001).
At baseline, less than 15% of women reported “good” or “very good” satisfaction with sexual intercourse. This increased to 33.6% and 39.1% with dapoxetine 30 mg and 60 mg, respectively (vs. 19.4% with placebo, p<.01).
Researchers said these findings confirm results from a separate study investigating how premature ejaculation affects female partners, specifically the significant impact in terms of lower perceived control over ejaculation, lower satisfaction with sexual intercourse, higher ejaculation-related personal distress, and/or interpersonal difficulty in the relationship when compared with female partners of men without premature ejaculation.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.